Mitochondrial complex I deficiency
MONDO:0100133A type of mitochondrial disease charcterized by macrocephaly (large head) with progressive leukodystrophy, encephalopathy, hypertrophic cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. The disease is caused by mutations in any of many genes and the inheritance pattern depends on the responsible gene.
Also known as: NADH coenzyme Q reductase deficiency, complex 1 mitochondrial respiratory chain deficiency, isolated NADH-CoQ reductase deficiency, isolated NADH-coenzyme Q reductase deficiency, isolated NADH-ubiquinone reductase deficiency, isolated complex I deficiency, isolated mitochondrial respiratory chain complex I deficiency, mitochondrial respiratory chain complex I deficiency
14 clinical trials for this condition and its sub-types, 2 tagged with Mitochondrial complex I deficiency itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mitochondrial complex I deficiency
-
1 sub-type
-
37 sub-types
- Leber hereditary optic neuropathy, autosomal recessive 0 trials Sub-types →
- Mitochondrial complex I deficiency, nuclear type 1 0 trials
- Mitochondrial complex I deficiency, nuclear type 10 0 trials
- Mitochondrial complex I deficiency, nuclear type 11 0 trials
- Mitochondrial complex I deficiency, nuclear type 12 0 trials
- Mitochondrial complex I deficiency, nuclear type 13 0 trials
- Mitochondrial complex I deficiency, nuclear type 14 0 trials
- Mitochondrial complex I deficiency, nuclear type 15 0 trials
- Mitochondrial complex I deficiency, nuclear type 16 0 trials
- Mitochondrial complex I deficiency, nuclear type 17 0 trials
- Mitochondrial complex I deficiency, nuclear type 18 0 trials
- Mitochondrial complex I deficiency, nuclear type 19 0 trials
- Mitochondrial complex I deficiency, nuclear type 2 0 trials
- Mitochondrial complex I deficiency, nuclear type 21 0 trials
- Mitochondrial complex I deficiency, nuclear type 22 0 trials
- Mitochondrial complex I deficiency, nuclear type 23 0 trials
- Mitochondrial complex I deficiency, nuclear type 24 0 trials
- Mitochondrial complex I deficiency, nuclear type 25 0 trials
- Mitochondrial complex I deficiency, nuclear type 26 0 trials
- Mitochondrial complex I deficiency, nuclear type 27 0 trials
- Mitochondrial complex I deficiency, nuclear type 28 0 trials
- Mitochondrial complex I deficiency, nuclear type 29 0 trials
- Mitochondrial complex I deficiency, nuclear type 3 0 trials
- Mitochondrial complex I deficiency, nuclear type 30 0 trials
- Mitochondrial complex I deficiency, nuclear type 31 0 trials
- Mitochondrial complex I deficiency, nuclear type 32 0 trials
- Mitochondrial complex I deficiency, nuclear type 33 0 trials
- Mitochondrial complex I deficiency, nuclear type 34 0 trials
- Mitochondrial complex I deficiency, nuclear type 36 0 trials
- Mitochondrial complex I deficiency, nuclear type 37 0 trials
- Mitochondrial complex I deficiency, nuclear type 39 0 trials
- Mitochondrial complex I deficiency, nuclear type 4 0 trials
- Mitochondrial complex I deficiency, nuclear type 5 0 trials
- Mitochondrial complex I deficiency, nuclear type 6 0 trials
- Mitochondrial complex I deficiency, nuclear type 7 0 trials
- Mitochondrial complex I deficiency, nuclear type 8 0 trials
- Mitochondrial complex I deficiency, nuclear type 9 0 trials
Most studied deeper sub-types
-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug aims to help mitochondrial disease patients walk farther
Disease control CompletedThis Phase 3 trial tested a daily injection called elamipretide in 102 adults with primary mitochondrial myopathy, a genetic condition that causes muscle weakness and fatigue. Participants received either the drug or a placebo for 48 weeks. The main goal was to see if the drug co…
Phase 3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC